Gene expression studies demonstrate that the K-ras/Erk MAP kinase signal transduction pathway and other novel pathways contribute to the pathogenesis of cumene-induced lung tumors

Toxicologic Pathology

Volumn 36, Issue 5, 2008, Pages 743-752

  Wakamatsu, Nobuko ^a   Collins, Jennifer B ^a   Parker, Joel S ^b   Tessema, Mathewos ^c   Clayton, Natasha P ^a   Ton, Thai Vu T ^a   Hong, Hue Hua L ^a   Belinsky, Steven ^c   Devereux, Theodora R ^a   Sills, Robert C ^a   Lahousse, Stephanie A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b Statistics and Public Health Research Division   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Epigenetics; Histone deacetylation; K ras; Lung cancer; MAPK; Microarray; Mouse

Indexed keywords

CUMENE; HISTONE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; LUNG TUMOR; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PATHOGENESIS; POST HOC ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANIMALS; BENZENE DERIVATIVES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED STRAINS; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

MUS;

EID: 49749117969     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623308320801     Document Type: Article

References (83)

1. Airley, RE, and A Mobasheri (2007). Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy, 53, 233-56.
2. Barry, WT, AB Nobel, and FA Wright (2005). Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics, 21, 1943-49.
3. Berns, H, R Humar, B Hengerer, FN Kiefer, and EJ Battegay (2000). RACK1 is up-regulated in angiogenesis and human carcinomas. Faseb J, 14, 2549-58.
4. Bhattacharjee, A, WG Richards, J Staunton, C Li, S Monti, P Vasa, C Ladd, J Beheshti, R Bueno, M Gillette, M Loda, G Weber, EJ Mark, ES Lander, W Wong, BE Johnson, TR Golub, DJ Sugarbaker, and M Meyerson (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adeno-carcinoma subclasses. Proc Natl Acad Sci USA, 98, 13790-95.
5. Bonner, AE, WJ Lemon, TR Devereux, RA Lubet, and M You (2004). Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene, 23, 1166-76.
6. Chang, GC, KJ Liu, CL Hsieh, TS Hu, S Charoenfuprasert, HK Liu, KT Luh, LH Hsu, CW Wu, CC Ting, CY Chen, KC Chen, TY Yang, TY Chou, WH Wang, J Whang-Peng, and NY Shih (2006). Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res, 12, 5746-54.
7. Chang, HC, LT Liu, and WC Hung (2004). Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal, 16, 675-79.
8. Chen, PP, WJ Li, Y Wang, S Zhao, DY Li, LY Feng, XL Shi, HP Koeffler, XJ Tong, and D Xie (2007). Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE, 2, e534.
9. Chen, YF, HH Chiu, CH Wu, JY Wang, FM Chen, WH Tzou, SJ Shin, and SR Lin (2003). Retinoblastoma protein (pRB) was significantly phosphorylated through a Ras-to-MAPK pathway in mutant K-ras stably transfected human adrenocortical cells. DNA Cell Biol, 22, 657-64.
10. Chu, YW, PC Yang, SC Yang, YC Shyu, MJ Hendrix, R Wu, and CW Wu (1997). Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol, 17, 353-60.
11. Collins, BJ, W Kleeberger, and DW Ball (2004). Notch in lung development and lung cancer. Seminars in Cancer Biology, 14, 357-64.
12. Crews, D, and JA McLachlan (2006). Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology, 147, S4-10.
13. Daniel, VC, CD Peacock, and DN Watkins (2006). Developmental signalling pathways in lung cancer. Respirology, 11, 234-40.
14. Durai, R, SY Yang, KM Sales, AM Seifalian, G Goldspink, and MC Winslet (2007). Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer. Colorectal Dis, 9, 625-31.
15. Eberharter, A, and PB Becker (2002). Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Reports, 3, 224-29.
16. Fujita, H, F Okada, J Hamada, M Hosokawa, T Moriuchi, RC Koya, and N Kuzumaki (2001). Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer, 93, 773-80.
17. Gan, Y, YH Shen, J Wang, X Wang, B Utama, J Wang, and XL Wang (2005). Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J Biol Chem, 280, 16467-75.
18. Garber, ME, OG Troyanskaya, K Schluens, S Petersen, Z Thaesler, M Pacyna-Gengelbach, M van de Rijn, GD Rosen, CM Perou, RI Whyte, RB Altman, PO Brown, D Botstein, and I Petersen (2001). Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A, 98, 13784-89.
19. Grunewald, TG, U Kammerer, C Winkler, D Schindler, A Sickmann, A Honig, and E Butt (2007). Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer, 96, 296-305.
20. Hajra, KM, and ER Fearon (2002). Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer, 34, 255-68.
21. Hellebrekers, DM, V Melotte, E Vire, E Langenkamp, G Molema, F Fuks, JG Herman, W Van Criekinge, AW Griffioen, and M van Engeland (2007). Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res, 67, 4138-48.
22. Hirabayashi, K, F Numa, Y Suminami, A Murakami, T Murakami, and H Kato (1998). Altered proliferative and metastatic potential associated with increased expression of syndecan-1. Tumour Biol, 19, 454-63.
23. Hong, HL, TT Ton, Y Kim, N Wakamatsu, RC Sills, and SA Lahousse (2008). Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from B6C3F1 mice exposed to cumene. Toxicol Pathol. In Press.
24. Hurbin, A, L Dubrez, JL Coll, and MC Favrot (2002). Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem, 277, 49127-33.
25. Jacob, ST, and T Motiwala (2005). Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther, 12, 665-72.
26. Kikuchi, T, M Toyota, F Itoh, H Suzuki, T Obata, H Yamamoto, H Kakiuchi, M Kusano, JP Issa, T Tokino, and K Imai (2002). Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene, 21, 2741-49.
27. Kim, SH, MO Kim, P Gao, CA Youm, HR Park, TS Lee, KS Kim, JG Suh, HT Lee, BJ Park, ZY Ryoo, and TH Lee (2005). Overexpression of extracellular superoxide dismutase (EC-SOD) in mouse skin plays a protective role in DMBA/TPA-induced tumor formation. Onc Res, 15, 333-41.
28. Kim, SK, HR Jang, JH Kim, SM Noh, KS Song, MR Kim, SY Kim, YI Yeom, NS Kim, HS Yoo, and YS Kim (2006). The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration. Biochem Biophys Res Comm, 349, 1032-40.
29. Kranenburg, O, AJ van der Eb, and A Zantema (1995). Cyclin-dependent kinases and pRb: regulators of the proliferation-differentiation switch. FEBS Lett, 367, 103-6.
30. Kristeleit, R, L Stimson, P Workman, and W Aherne (2004). Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs, 9, 135-54.
31. Lambertini, L, K Surin, TV Ton, N Clayton, JK Dunnick, Y Kim, HH Hong, TR Devereux, and RC Sills (2005). Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy). Toxicol Pathol, 33, 292-99.
32. Lavoie, JN, G L'Allemain, A Brunet, R Muller, and J Pouyssegur (1996). Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem, 271, 20608-16.
33. Levine, AA, Z Guan, A Barco, S Xu, ER Kandel, and JH Schwartz (2005). CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. Proc Natl Acad Sci U S A, 102, 19186-91.
34. Li, J, M Gorospe, D Hutter, J Barnes, SM Keyse, and Y Liu (2001). Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation. Mol Cell Biol, 21, 8213-24.
35. Lu, Y, W Lemon, PY Liu, Y Yi, C Morrison, P Yang, Z Sun, J Szoke, WL Gerald, M Watson, R Govindan, and M You (2006). A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Medicine, 3, e467.
36. Lue, H, A Kapurniotu, G Fingerle-Rowson, T Roger, L Leng, M Thiele, T Calandra, R Bucala, and J Bernhagen (2006). Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal, 18, 688-703.
37. Mao, X, E Seidlitz, K Ghosh, Y Murakami, and HP Ghosh (2003). The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res, 63, 7979-85.
38. Mariadason, JM, GA Corner, and LH Augenlicht (2000). Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res, 60, 4561-72.
39. Mazieres, J, D Tovar, B He, N Acosta-Jacobo, C Marty-Detraves, C Clanet, A Pradines, DM Jablons, and G Favre (2007). Epigenetic regulation of RhoB loss of expression in lung cancer. BMC Cancer, 7, 220.
40. Nicod, M, S Michlig, M Flahaut, M Salinas, N Fowler Jaeger, JD Horisberger, BC Rossier, and D Firsov (2002). A novel vasopressin-induced transcript promotes MAP kinase activation and ENaC downregulation. EMBO J, 21, 5109-17.
41. (2007). National Toxicology Program, toxicology and carcinogenicity studies of cumene in F344/N rats and B6C3F1 mice (inhalation studies).. NTP Technical Report 542.
42. O'Rourke, JP, GC Newbound, JA Hutt, and J DeWille (1999). CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis. J Biol Chem, 274, 16582-89.
43. Ota, H, E Tokunaga, K Chang, M Hikasa, K Iijima, M Eto, K Kozaki, M Akishita, Y Ouchi, and M Kaneki (2006). Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene, 25, 176-85.
44. Owens, DM, and SM Keyse (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene, 26, 3203-13.
45. Peeper, DS, TM Upton, MH Ladha, E Neuman, J Zalvide, R Bernards, JA DeCaprio, and ME Ewen (1997). Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature, 386, 177-81.
46. Peng, Y, D Stewart, W Li, M Hawkins, S Kulak, B Ballermann, and N Jahroudi (2007). Irradiation modulates association of NF-Y with histone-modifying cofactors PCAF and HDAC. Oncogene, 26, 7576-83.
47. Pillinger, MH, N Marjanovic, SY Kim, JU Scher, P Izmirly, S Tolani, V Dinsell, YC Lee, MJ Blaser, and SB Abramson (2005). Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs. J Biol Chem, 280, 9973-79.
48. Sanda, T, T Okamoto, Y Uchida, H Nakagawa, S Iida, S Kayukawa, T Suzuki, T Oshizawa, T Suzuki, N Miyata, and R Ueda (2007). Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia, 21, 2344-53.
49. Sasai, K, K Kakumoto, H Hanafusa, and T Akagi (2007). The Ras-MAPK pathway downregulates Caveolin-1 in rodent fibroblast but not in human fibroblasts: implications in the resistance to oncogene-mediated transformation. Oncogene, 26, 449-55.
50. Shaul, YD, and R Seger (2007). The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta, 1773, 1213-26.
51. Shen, Y, Z Jia, RG Nagele, H Ichikawa, and GS Goldberg (2006). SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res, 66, 1543-52.
52. Shimada, M, I Hernandez-Gonzalez, I Gonzalez-Robayna, and JS Richards (2006). Paracrine and autocrine regulation of epidermal growth factor-like factors in cumulus oocyte complexes and granulosa cells: key roles for prostaglandin synthase 2 and progesterone receptor. Mol Endocrinol, 20, 1352-65.
53. Sills, RC, HL Hong, A Greenwell, RA Herbert, GA Boorman, and TR Devereux (1995). Increased frequency of K-ras mutations in lung neoplasms from female B6C3F1 mice exposed to ozone for 24 or 30 months. Carcinogenesis, 16, 1623-28.
54. Smith, HO, KK Leslie, M Singh, CR Qualls, CM Revankar, NE Joste, and ER Prossnitz (2007). GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol, 196, 386 e1-9. discussion 386 e9-11.
55. Stebbing, J, M Bower, N Syed, P Smith, V Yu, and T Crook (2006). Epigenetics: an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics, 7, 747-57.
56. Swant, JD, BE Rendon, M Symons, and RA Mitchell (2005). Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem, 280, 23066-72.
57. Sweet-Cordero, A, S Mukherjee, A Subramanian, H You, JJ Roix, C Ladd-Acosta, J Mesirov, TR Golub, and T Jacks (2005). An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet, 37, 48-55.
58. Takahashi, M, K Hayashi, K Yoshida, Y Ohkawa, T Komurasaki, A Kitabatake, A Ogawa, W Nishida, M Yano, M Monden, and K Sobue (2003). Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation, 108, 2524-29.
59. Tam, CW, AS Cheng, RY Ma, KM Yao, and SY Shiu (2006). Inhibition of prostate cancer cell growth by human secreted PDZ domain-containing protein 2, a potential autocrine prostate tumor suppressor. Endocrinology, 147, 5023-33.
60. Teis, D, N Taub, R Kurzbauer, D Hilber, ME de Araujo, M Erlacher, M Offterdinger, A Villunger, S Geley, G Bohn, C Klein, MW Hess, and LA Huber (2006). p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol, 175, 861-68.
61. Tennis, M, M Van Scoyk, and RA Winn (2007). Role of the wnt signaling pathway and lung cancer. J Thorac Oncol, 2, 889-92.
62. Terraube, V, R Pendu, D Baruch, MF Gebbink, D Meyer, PJ Lenting, and CV Denis (2006). Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost, 4, 519-26.
63. Thullberg, M, J Bartkova, S Khan, K Hansen, L Ronnstrand, J Lukas, M Strauss, and J Bartek (2000). Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors. FEBS Lett, 470, 161-66.
64. Toyooka, S, M Tokumo, H Shigematsu, K Matsuo, H Asano, K Tomii, S Ichihara, M Suzuki, M Aoe, H Date, AF Gazdar, and N Shimizu (2006). Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res, 66, 1371-75.
65. Toyooka, S, K Tsukuda, M Ouchida, M Tanino, Y Inaki, K Kobayashi, M Yano, J Soh, T Kobatake, N Shimizu, and K Shimizu (2003). Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep, 10, 1455-59.
66. Tsai, YS, HC Chang, LY Chuang, and WC Hung (2005). RNA silencing of Cks1 induced G2/M arrest and apoptosis in human lung cancer cells. IUBMB Life, 57, 583-89.
67. Tsunezuka, Y, H Kinoh, T Takino, Y Watanabe, Y Okada, A Shinagawa, H Sato, and M Seiki (1996). Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res, 56, 5678-83.
68. Umesako, S, S Iiga, M Takahashi, K Imura, N Mori, DP Hong, CW Song, O Niwa, and M Okumoto (2007). Distinct pattern of allelic loss and inactivation of cadherin 1 and 5 genes in mammary carcinomas arising in p53(+/-) mice. J Radiat Res, 48, 143-52.
69. Volm, M, R Koomagi, J Mattern, and T Efferth (2002). Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases. Clin Ex Metastasis, 19, 385-90.
70. von Rahden, BH, BL Brucher, C Langner, JR Siewert, HJ Stein, and M Sarbia (2006). Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine. Br J Surg, 93, 1424-32.
71. Wako, K, T Kawasaki, K Yamana, K Suzuki, S Jiang, H Umezu, T Nishiyama, K Takahashi, T Hamakubo, T Kodama, and M Naito (2008). Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol, 61, 448-454.
72. Weng, L, H Dai, Y Zhan, Y He, SB Stepaniants, and DE Bassett (2006). Rosetta error model for gene expression analysis. Bioinformatics, 22, 1111-21.
73. Williams, TM, F Medina, I Badano, RB Hazan, J Hutchinson, WJ Muller, NG Chopra, PE Scherer, RG Pestell, and MP Lisanti (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem, 279, 51630-46.
74. Wu, G, Z Guo, X Chang, MS Kim, JK Nagpal, J Liu, JM Maki, KI Kivirikko, SP Ethier, B Trink, and D Sidransky (2007). LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Cancer Res, 67, 4123-29.
75. Xi, L, MC Coello, VR Litle, S Raja, WE Gooding, SA Yousem, T El-Hefnawy, RJ Landreneau, JD Luketich, and TE Godfrey (2006). A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res, 12, 2484-91.
76. Yang, Y, BG Goldstein, H Nakagawa, and JP Katz (2007). Kruppel-like factor 5 activates MEK/ERK signaling via EGFR in primary squamous epithelial cells. Faseb J, 21, 543-50.
77. Yoon, DK, CH Jeong, HO Jun, KH Chun, JH Cha, JH Seo, HY Lee, YK Choi, BJ Ahn, SK Lee, and KW Kim (2007). AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. Cancer Lett, 254, 111-18.
78. Yoshikawa, M, K Hishikawa, T Marumo, and T Fujita (2007). Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol, 18, 58-65.
79. Younes, M, RW Brown, M Stephenson, M Gondo, and PT Cagle (1997). Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer, 80, 1046-51.
80. Yu, YP, G Yu, G Tseng, K Cieply, J Nelson, M Defrances, R Zarnegar, G Michalopoulos, and JH Luo (2007). Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res, 67, 8043-50.
81. Yuan, BZ, AM Jefferson, KT Baldwin, SS Thorgeirsson, NC Popescu, and SH Reynolds (2004). DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene, 23, 1405-11.
82. Zhang, JS, L Wang, H Huang, M Nelson, and DI Smith (2001). Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells. Genes Chromosomes Cancer, 30, 123-35.
83. Zhou, X, VM Richon, AH Wang, XJ Yang, RA Rifkind, and PA Marks (2000). Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. Proc Natl Acad Sci U S A, 97, 14329-33.